BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL. - Borchmann, P.; Moccia, A. A.; Greil, R.; Schneider, G.; Hertzberg, M.; Schaub, V.; Hüttmann, A.; Keil, F.; Dierlamm, J.; Hänel, M.; Novak, U.; Meissner, J.; et al. (Hematological oncology, 2023)